Posted On: 11/16/2014 9:21:03 AM
Post# of 30070
.......wouldn't the (extended) L-002 studies have to be completed 1st, in order to arrive at final determination in V1 vs. V2 RUO commercialization efforts?
......has ICON made final decision on univariant vs. multivariant validation results?
.......seems ICON would finalize validation on which version they are going to RUO market with before dispencing preorder tests
http://globenewswire.com/news-release/2014/10...est-R.html
Quote:
"Based on the strength of these results, the company has expanded the inclusion criteria to also enroll patients diagnosed with mild Alzheimer's disease. 68 additional subjects will be recruited, including 34 mild-to-severe Alzheimer's patients, and 34 healthy controls. Amarantus anticipates completing enrollment of the 68 patient LP-002 extension in the fourth quarter and will announce data from an in-depth analysis from the full cohort of 140 subjects (72 patients + 68 patient extension) shortly thereafter."
......has ICON made final decision on univariant vs. multivariant validation results?
Quote:
"Amarantus believes the results from both Version 1 and Version 2 of LymPro are suitable for commercialization, and is validating both Version 1 and Version 2 for use in the Research Use Only (RUO) market."
.......seems ICON would finalize validation on which version they are going to RUO market with before dispencing preorder tests
http://globenewswire.com/news-release/2014/10...est-R.html
(0)
(0)
